Formulation and use patent issued to InMed for ocular delivery candidate
InMed Pharmaceuticals has been issued 3 US patents, one of which is for an ocular drug delivery formulation for potential use in AMD.
(Image credit: AdobeStock/Tierney)
InMed Pharmaceuticals has been issued 3 US patents, one of which is for an ocular drug delivery formulation for potential use in age-related macular degeneration (AMD). This formulation and use patent has been granted/allowed in the US, Europe, Australia, Japan, and India and is also pending in other jurisdictions.
According to the press release1 issued by the company, as of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use. The company noted that they will continue to pursue new chemical entity patents on the drug candidates for both its INM-901 program in Alzheimer’s disease, for which they also recently received patents, and INM-089 in dry AMD.
InMed’s President and CEO, Eric A. Adams, shared his excitement for these positive steps forward by saying, “We are pleased to announce these US patent issuances which help increase the commercial value of our programs and ensure the long-term protection of our drug research and development efforts. We are committed to continuing to build our patent portfolio to protect our novel drug candidates, methods of manufacturing these drugs, how they are formulated and how they are used to support the development of new treatments for diseases with high unmet medical needs.”1
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of 3 separate programs in the treatment of Alzheimer’s, ocular, and dermatological indications. Together with subsidiary BayMedica, these companies are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates.
